Vitura Health Limited (VIT.AX)
| Previous close | 0.0740 |
| Open | 0.0760 |
| Bid | 0.0750 x N/A |
| Ask | 0.0760 x N/A |
| Day's range | 0.0740 - 0.0760 |
| 52-week range | 0.0680 - 0.3850 |
| Volume | |
| Avg. volume | 361,060 |
| Market cap | 43.766M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 7.60 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.01 (12.66%) |
| Ex-dividend date | 04 Sept 2023 |
| 1y target est | N/A |
- GlobeNewswire
Cronos Enters Australian Cannabis Market
TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited (“Vitura”) (ASX: VIT). Cronos owns approximately 10% of the common shares of Vitura, formerly known as Cronos Australia, and will supply cannabis for Vitura. “Supplying the Australian market, which has grown significantly in the past three
- GlobeNewswire
PharmAla Files Audited Financials for Year Ending August 31, 2023
Highlights include Revenue Growth, Expansion of IP Licensing, and formation of Cortexa Joint VentureVANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to file its audited financial statements for the year ended on August 31, 2023. Following is a short list of th
- GlobeNewswire
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian
